Thalidomide neurotoxicity: prospective study in patients with lupus erythematosus.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 15210897.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The authors prospectively followed 14 patients treated with thalidomide for cutaneous lupus erythematosus (CLE), in order to evaluate the occurrence of peripheral neuropathy (PN) and to assess whether PN correlates with thalidomide dose. The patients were followed for up to 24 months with neurologic and electrophysiologic evaluations. Seven patients (50%) developed sensory axonal PN. The median time free from PN was 14 months. PN occurred after 10 months in the majority of patients. No correlations were found between thalidomide cumulative dose and occurrence of PN (Mann-Whitney U test; p > 0.16).
Medical subject headings
- Immunosuppressive Agents
- Lupus Erythematosus, Cutaneous
- Neurotoxicity Syndromes
- Peripheral Nervous System Diseases
- Thalidomide